Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. FDX
3. CBRS
4. USO
5. SPY
6. MU
7. KBH
8. HON
9. HTZ
10. GOOGL

Go back to Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma

Karyopharm Therapeutics (KPTI) PT Raised to $21 at Wedbush

May 1, 2018 9:59 AM EDT

Wedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $21.00 (from $19.00) while maintaining a Outperform rating.

Analyst David Nierengarten commented, "Topline results from STORM met our expectations and should be sufficient to support accelerated approval (AA) for selinexor plus dex in... More

Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'

May 1, 2018 7:58 AM EDT

RBC Capital raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $24.00 (from $22.00) while maintaining a Outperform rating.

Analyst Brian Abrahams commented, "Expanded ph.II STORM data for selinexor in MM looks to have met the ORR/DOR bar for confirming its likely... More

Karyopharm Therapeutics (KPTI) to Resume Trading at 4:35 pm ET

April 30, 2018 4:16 PM EDT

Karyopharm Therapeutics (NASDAQ: KPTI) to Resume Trading at 4:35 pm ET

... More